Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection.
Petra BrodskaPetr PanznerDalibor SedlacekMilan TerlPetra CetkovskaPublished in: Dermatologic therapy (2020)
Dupilumab is a monoclonal antibody against interleukin 4 (IL-4) receptor α that blocks signaling from IL-4 and IL-13, essential mediators of T helper 2 (Th2) pathway. To date, all clinical trials investigating the use of dupilumab excluded patients with human immunodeficiency virus. Herein, we describe the safe and successful use of dupilumab in a patient with atopic dermatitis, severe therapy resistant asthma, and HIV infection.
Keyphrases
- atopic dermatitis
- human immunodeficiency virus
- antiretroviral therapy
- monoclonal antibody
- clinical trial
- hiv infected
- hepatitis c virus
- case report
- hiv aids
- hiv positive
- chronic obstructive pulmonary disease
- lung function
- early onset
- stem cells
- immune response
- cystic fibrosis
- open label
- mesenchymal stem cells
- phase ii